Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | S1PR4 | O95977 | 5/20 | 0.42 |
| ▸ | CTSB | P07858 | 1/20 | 0.41 |
| ▸ | CTSH | P09668 | 1/20 | 0.41 |
| ▸ | CNR2 | P34972 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.40 |
| ▸ | NPC1 | O15118 | 3/20 | 0.38 |
| ▸ | RAB9A | P51151 | 3/20 | 0.38 |
| ▸ | CFTR | P13569 | 1/20 | 0.38 |
| ▸ | TXNRD1 | Q16881 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.37 |
| ▸ | HTT | P42858 | 1/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | MAOA | P21397 | 1/20 | 0.36 |
| ▸ | MERTK | Q12866 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29391783 | 0.82 | TXNRD1 (0.38) | S1PR4CNR2ALDH1A1CFTRTXNRD1 | |
| SCHEMBL17490468 | 0.82 | MERTK (0.51) | S1PR4CNR2ALDH1A1CFTRTXNRD1 | |
| SCHEMBL24251675 | 0.82 | TXNRD1 (0.38) | S1PR4CNR2ALDH1A1CFTRTXNRD1 | |
| SCHEMBL15716302 | 0.78 | NPC1 (0.46) | S1PR4CTSBCTSHALDH1A1NPC1 | |
| SCHEMBL22595337 | 0.77 | CNR2 (0.39) | S1PR4CNR2ALDH1A1CFTRTXNRD1 | |
| SCHEMBL24992474 | 0.77 | HCRTR1 (0.40) | CNR2CFTRTXNRD1 | |
| SCHEMBL20278129 | 0.77 | CTSB (0.44) | CTSBCTSHALDH1A1NPC1RAB9A | |
| SCHEMBL20278131 | 0.77 | APP (0.46) | S1PR4CTSBCTSHALDH1A1NPC1 | |
| SCHEMBL18952487 | 0.77 | S1PR4 (0.62) | S1PR4ALDH1A1NPC1RAB9ALMNA | |
| SCHEMBL23977890 | 0.76 | CNR2 (0.50) | CNR2ALDH1A1LMNASMN1; SMN2MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250034110-A1 | LPAR1 ANTAGONISTS AND USES THEREOF | Pipeline Therapeutics, Inc. | 2025-01-30 | — | — | US | disclosed |
| EP-4380560-A1 | LPAR1 ANTAGONISTS AND USES THEREOF | Contineum Therapeutics, Inc. (US) | 2024-06-12 | — | — | EP | disclosed |
| CN-118043041-A | LPAR1 antagonists and uses thereof | 康蒂内乌姆医疗公司 | 2024-05-14 | — | — | CN | disclosed |
| WO-2023014908-A1 | LPAR1 ANTAGONISTS AND USES THEREOF | Pipeline Therapeutics, Inc. (US) | 2023-02-09 | — | — | WO | disclosed |
| WO-2023014908-A1 | LPAR1 ANTAGONISTS AND USES THEREOF | Pipeline Therapeutics, Inc. (US) | 2023-02-09 | — | — | WO | disclosed |
| CN-102702171-B | Process for producing acid adduct salt of polyacidic base compound | KOWA CO | 2014-09-10 | — | — | CN | disclosed |
| EP-1627875-B1 | METHOD FOR PRODUCING CYCLIC DIAMINE DERIVATIVE OR SALT THEREOF | KOWA CO (JP) | 2013-07-31 | — | — | EP | disclosed |
| US-7459552-B2 | Method for producing cyclic diamine derivative or salt thereof | KOWA CO., LTD. (JP) | 2008-12-02 | — | — | US | disclosed |
| US-20060293519-A1 | Method for producing cyclic diamine derivative or salt thereof | KOWA CO., LTD. (JP) | 2006-12-28 | — | — | US | disclosed |
| CN-1816542-A | 2, 4-bis (trifluoroethoxy) pyridine compound and medicine containing the same | KOWA CO (JP) | 2006-08-09 | — | — | CN | disclosed |
| EP-1627875-A1 | METHOD FOR PRODUCING CYCLIC DIAMINE DERIVATIVE OR SALT THEREOF | Kowa Co., Ltd. (JP) | 2006-02-22 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060293519-A1 | Method for producing cyclic diamine derivative or salt thereof | NNT, APRT, SAT1 | S1PR4 1248/4885CTSB 3675/4885CTSH 3914/4885 |
| US-20250034110-A1 | LPAR1 ANTAGONISTS AND USES THEREOF | LPAR1, LPAR2, LPAR3 | S1PR4 41/4885CTSB 1216/4885CTSH 871/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.